In our latest post AACR coverage I wanted to explore a controversial topic arising from the annual meeting from several different angles.

Beyond the hype and rah-rah of the latest MD Anderson data on cord blood NK cells complexed with Affimed’s NK cell engager, what’s left?  Is the noise well deserved and what context or lens should be using to view the kaleidoscope?  What do experts really think behind the scenes?

Biotech is often a bit of roller coaster of a ride at the best of times, never mind when it’s early stage of a new game in town.

Here we take a rather different perspective from the mainstream thinking and explain our thinking and reasons why…

BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.

This content is restricted to subscribers

Posted by